Show simple item record

dc.contributor.authorManas, D.
dc.contributor.authorBell, Jon
dc.contributor.authorMealing, S.
dc.contributor.authorDavies, H.
dc.contributor.authorBaker, H.
dc.contributor.authorHolmes, H.
dc.contributor.authorHubner, Richard A
dc.date.accessioned2020-10-06T13:33:44Z
dc.date.available2020-10-06T13:33:44Z
dc.date.issued2020en
dc.identifier.citationManas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, et al. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol. 2020.en
dc.identifier.pmid32958370en
dc.identifier.doi10.1016/j.ejso.2020.08.027en
dc.identifier.urihttp://hdl.handle.net/10541/623314
dc.description.abstractIntroduction: The aim of the study is to estimate the cost-effectiveness of TheraSphere against other embolic treatments in a population with early to intermediate stage hepatocellular carcinoma (HCC) who are unresectable at presentation and are eligible for transarterial embolization (TAE), conventional transarterial chemoembolization (cTACE) or drug-eluting bead TACE (DEB-TACE). Materials and methods: A Markov model was constructed using a UK National Health Service (NHS) perspective, a 20-year time horizon, and four-week cycles. The eight health states included 'watch and wait', 'transplantation' (pre-, post and post (No HCC)), 'resection', "no HCC other", 'pharmacological management' and 'death'. Clinical data were sourced from literature and expert opinion. Resource use and costs were reflective of the NHS, and benefits were quantified using Quality-Adjusted Life Years (QALYs), with utility weights sourced from literature. Comparators were TAE, cTACE and DEB-TACE. The primary output was the Incremental Cost-Effectiveness Ratio (ICER) expressed as cost per QALY gained. An ICER of under £20,000/QALY gained for an intervention is cost-effective and represents efficient use of healthcare resources. Extensive deterministic and probabilistic sensitivity analyses were undertaken. Results: TheraSphere patients were predicted to gain 0.7 additional QALYs compared to all other treatments. The base case ICERs for TheraSphere were £17,300, £17,279 and £23,020 per QALY gained compared to TAE, cTACE and DEB-TACE, respectively. In the TheraSphere cohort, 87% more patients were predicted to achieve downstaging compared to all other treatment options. Conclusions: This study indicates that treatment with TheraSphere is a potentially cost-effective option for patients with early to intermediate stage HCC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ejso.2020.08.027en
dc.titleThe cost-effectiveness of therasphere in patients with hepatocellular carcinoma who are eligible for transarterial embolizationen
dc.typeArticleen
dc.contributor.departmentNewcastle upon Tyne NHS Trust, Freeman Hospital Freeman Road High Heaton Newcastle upon Tyne, NE7 7DN, UKen
dc.identifier.journalEuropean Journal of Surgical Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record